Fig. 1From: Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications?Utilisation of the COX-2 inhibitors (a) in the Australian concession beneficiary population from 2000 to 2008; and b over the initial year of each drug’s subsidy on the Australian Pharmaceutical Benefits Scheme (date of introduction shown)Back to article page